Chronic and rare disease patients face battles every day that other Americans do not have to deal with. From access to adequate health care, to the cost of treatment and medications to treat their conditions—Policy issues can present opportunities to make meaningful, lasting change for everyone.
WASHINGTON, DC – January 17, 2024 — Patient and provider groups were thrilled to learn
the US Department of Health and Human Services (HHS) dropped its appeal this week
challenging a US District Court ruling to make access to prescription drugs easier for people
living with serious, chronic conditions. This move ensures that the 2020 rule on cost-sharing is
in full effect, requiring insurers to count copay assistance towards patient cost-sharing. We now
urge HHS to enforce this ruling and issue immediate instructions to issuers on how to comply.
WASHINGTON – Today, Senator Tim Scott’s (R-S.C.) and Senator Cory Booker’s (D-N.J.) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 passed out of the Senate Committee on Health, Education, Labor and Pensions. This legislation reauthorizes the Health Resources and Services Administration’s Sickle Cell Disease Treatment Demonstration Program beyond fiscal year 2023 through fiscal year 2028.
The All Copays Count Coalition comprises more than 80 national 501c3 non-profit, non-partisan patient advocacy and provider organizations representing millions of people living with serious, complex, chronic illness. The people we represent need full and ongoing access to medical care, including specialty medications, to treat their conditions and to keep them healthy.